NASDAQ: ASBPAspire Biopharma Holdings Inc Stock
$0.66+0.02 (+3.13%)
Updated Mar 27, 2025
ASBP Price
$0.66
Fair Value Price
N/A
Market Cap
$30.36M
52 Week Low
$0.52
52 Week High
$15.80
P/E
-1.22x
P/B
-37.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.23
Operating Cash Flow
-$161k
Beta
0.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ASBP Overview
PowerUp Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the interactive media, digital media, sports, and entertainment sectors. PowerUp Acquisition was incorporated in 2021 and is headquartered New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASBP's potential to beat the market
- ASBP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ASBP
RankedUnranked of 477
RankedUnranked of 477
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.58 | A | |
| $8.46 | A | |
| $126.40 | A |
Be the first to know about important ASBP news, forecast changes, insider trades & much more!
ASBP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASBP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASBP is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ASBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ASBP due diligence checks available for Premium users.
Valuation
ASBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.22x
Industry
-123.64x
Market
31.08x
ASBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-37.88x
Industry
4.52x
ASBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$243.6k
Profit Margin
0%
ASBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$184.0k
Liabilities
$985.6k
Debt to equity
-1.23
ASBP's short-term liabilities ($985.63k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASBP's short-term assets ($184.04k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.1M
Investing
-$13.8M
Financing
$11.7M
ASBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASBP vs Biotech Stocks
Aspire Biopharma Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.